Skip to Content

Isatuximab-irfc (Sarclisa®) In Patients with Relapsed/Refractory Multiple Myeloma

Download PQI pdf 0.17MB

Last Updated: September 29, 2023

By: Jon Suyko, PharmD, BCPS

About this PQI

The purpose of this PQI is to discuss the option of using isatuximab-irfc with pomalidomide and dexamethasone in patients with relapsed/refractor multiple myeloma (RRMM) who have received at least 2 prior therapies including lenalidomide and a proteosome inhibitor or in combination with carfilzomib and dexamethasone in patients with RRMM who have received 1 to 3 prior lines of therapy.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI